Signatera for detecting molecular residual disease from solid tumour cancers

  • Medtech innovation briefing
  • MIB307
  • Published: 
Download (PDF)

Regulatory information

Signatera is a CE-marked class IVD General in vitro diagnostic medical device under the EU In Vitro Diagnostic Medical Devices Directive (IVDD).